Evidence map›Paper›PMID 25308211›Full record

Trial reportJournal of orthopaedic science : official journal of the Japanese Orthopaedic Association2014

Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study.

Yasuaki Nakagawa, Shogo Mukai, Shigeru Yamada, Masayuki Matsuoka, Eri Tarumi, Tadashi Hashimoto, Chieko Tamura, Atsushi Imaizumi, Jun Nishihira, Takashi Nakamura

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Efficacy and Safety of Curcumin andFrontiers in immunology · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yasuaki NakagawaDepartment of Orthopedic Surgery, National Hospital Organization, Kyoto Medical Center, 1-1 Fukakusa Mukaihata-cho Fushimi-ku, Kyoto, 612-8555, Japan, yanakaga@kyotolan.hosp.go.jp.
Shogo Mukai
Shigeru Yamada
Masayuki Matsuoka
Eri Tarumi
Tadashi Hashimoto
Chieko Tamura
Atsushi Imaizumi
Jun Nishihira
Takashi Nakamura

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously developed a surface-controlled water-dispersible form of curcumin and named it Theracurmin(®) (Theracurmin; Theravalues, Tokyo, Japan). The area under the blood concentration-time curve of Theracurmin in humans was 27-fold higher than that of curcumin powder. We determined the clinical effects of orally administered Theracurmin in patients with knee osteoarthritis during 8 weeks of treatment.

methodsFifty patients with knee osteoarthritis of Kellgren-Lawrence grade II or III and who were aged more than 40 years were enrolled in this randomized, double-blind, placebo-controlled, prospective clinical study. Placebo or Theracurmin containing 180 mg/day of curcumin was administered orally every day for 8 weeks. To monitor adverse events, blood biochemistry analyses were performed before and after 8 weeks of each intervention. The patients' knee symptoms were evaluated at 0, 2, 4, 6, and 8 weeks by the Japanese Knee Osteoarthritis Measure, the knee pain visual analog scale (VAS), the knee scoring system of the Japanese Orthopedic Association, and the need for nonsteroidal anti-inflammatory drugs.

resultsAt 8 weeks after treatment initiation, knee pain VAS scores were significantly lower in the Theracurmin group than in the placebo group, except in the patients with initial VAS scores of 0.15 or less. Theracurmin lowered the celecoxib dependence significantly more than placebo. No major side effects were observed with Theracurmin treatment.

conclusionTheracurmin shows modest potential for the treatment of human knee osteoarthritis.

Indexed as

Administration, OralAgedAnti-Inflammatory Agents, Non-SteroidalBiological AvailabilityCurcuminDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleOsteoarthritis, KneeProspective StudiesRadiographyRange of Motion, ArticularTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalCurcumin

Identifiers

PMID25308211
PMCPMC4244558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.